Simulations Plus (NASDAQ:SLP) Updates FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY25 earnings guidance on Wednesday. The company provided EPS guidance of $1.07 to $1.20 for the period, compared to the consensus EPS estimate of $0.63. The company issued revenue guidance of $90 million to $93 million, compared to the consensus revenue estimate of $91.76 million. Simulations Plus also updated its FY 2025 guidance to 1.070-1.200 EPS.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on SLP shares. KeyCorp began coverage on shares of Simulations Plus in a report on Monday, July 29th. They issued an “overweight” rating and a $47.00 price target on the stock. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research report on Thursday. Craig Hallum reaffirmed a “buy” rating and set a $56.00 price objective on shares of Simulations Plus in a report on Wednesday, July 3rd. JMP Securities started coverage on Simulations Plus in a research note on Tuesday, July 16th. They issued a “market perform” rating on the stock. Finally, BTIG Research cut their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $54.50.

Simulations Plus Stock Performance

NASDAQ:SLP traded down $0.59 on Friday, hitting $30.37. 117,811 shares of the stock were exchanged, compared to its average volume of 129,309. The stock has a market capitalization of $607.70 million, a price-to-earnings ratio of 64.50 and a beta of 0.69. The company’s 50-day moving average price is $33.20 and its 200 day moving average price is $40.76. Simulations Plus has a 52 week low of $29.37 and a 52 week high of $51.22.

Simulations Plus (NASDAQ:SLP) last issued its earnings results on Wednesday, October 23rd. The technology company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The company had revenue of $18.70 million during the quarter, compared to analysts’ expectations of $19.73 million. During the same quarter in the previous year, the company posted $0.18 EPS. The business’s revenue for the quarter was up 19.9% compared to the same quarter last year. As a group, equities research analysts predict that Simulations Plus will post 0.54 earnings per share for the current year.

Insider Buying and Selling at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $39.63, for a total transaction of $792,600.00. Following the completion of the sale, the director now owns 3,521,592 shares of the company’s stock, valued at $139,560,690.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders sold 60,750 shares of company stock valued at $2,145,055. Company insiders own 20.90% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.